Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

August 31, 2011

Study Completion Date

March 31, 2012

Conditions
Corneal Neovascularization
Interventions
DRUG

Ranibizumab

0.5mg subconjunctival dose of ranibizumab 3 days prior to corneal transplantation and at the time of corneal transplantation (total 2 injections).

Trial Locations (1)

33136

Bascom Palmer Eye Institute, Miami

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Miami

OTHER